scholarly article | Q13442814 |
P356 | DOI | 10.1177/1358863X15574321 |
P698 | PubMed publication ID | 25835349 |
P2093 | author name string | Ehrin J Armstrong | |
Ezra A Amsterdam | |||
John R Laird | |||
Gagan D Singh | |||
Debbie C Chen | |||
P2860 | cites work | Endothelial dysfunction: the first step toward coronary arteriosclerosis | Q37395620 |
Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. | Q37620353 | ||
Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication | Q38438066 | ||
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial | Q38456532 | ||
Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia | Q39357910 | ||
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease | Q39671945 | ||
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection | Q40630962 | ||
Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. | Q44950795 | ||
Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry | Q46215474 | ||
Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease | Q46638911 | ||
Mortality over a period of 10 years in patients with peripheral arterial disease | Q46786119 | ||
Quality of care among patients undergoing lower extremity revascularization. | Q51114226 | ||
Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. | Q54092413 | ||
Critical limb ischemia. | Q55052558 | ||
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) | Q56287926 | ||
The central role of the propensity score in observational studies for causal effects | Q56882400 | ||
Epidemiology, classification, and modifiable risk factors of peripheral arterial disease | Q24681271 | ||
The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database | Q24810579 | ||
Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension | Q28189678 | ||
Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease | Q28195786 | ||
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
Peripheral arterial disease detection, awareness, and treatment in primary care | Q28216456 | ||
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
The global pandemic of peripheral artery disease. | Q30352611 | ||
Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats | Q31027565 | ||
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). | Q31956512 | ||
Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis | Q33310785 | ||
Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. | Q34297015 | ||
Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis | Q34361910 | ||
ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society f | Q34503123 | ||
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 | ||
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. | Q35116739 | ||
The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease | Q35763822 | ||
ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascul | Q36426489 | ||
Gender-related variation in the clinical presentation and outcomes of critical limb ischemia | Q37205015 | ||
P433 | issue | 3 | |
P921 | main subject | circulatory system | Q11068 |
P304 | page(s) | 237-244 | |
P577 | publication date | 2015-04-02 | |
P1433 | published in | Vascular Medicine | Q7916445 |
P1476 | title | Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia | |
P478 | volume | 20 |
Q57621177 | 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) |
Q97094318 | Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease |
Q90489664 | Atherosclerosis knowledge - diagnosis and management in primary care |
Q38850458 | Contemporary evaluation and management of lower extremity peripheral artery disease. |
Q52717834 | Interventions for lower extremity peripheral artery disease. |
Q47700735 | Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention |
Q38685935 | Long-term outcomes in patients with critical limb ischemia and heart failure with preserved or reduced ejection fraction |
Q38834990 | Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia |
Q38574304 | Meta-analysis on autologous stem cell transplantation in the treatment of limb ischemic. |
Q96304410 | Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results |
Q54282563 | Vascular specialist response to Medicare Evidence Development Coverage Advisory Committee (MEDCAC) panel on peripheral artery disease of the lower extremities. |
Q44547282 | Vascular specialist response to medicare evidence development coverage advisory committee (MEDCAC) panel on peripheral artery disease of the lower extremities |
Search more.